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Available online 12 July 2016Dilated cardiomyopathy (DCM) is one of themain causes of heart failure (called cardiomyopathies) in adults. Al-
terations in epigenetic regulation (i.e., DNAmethylation) have been implicated in the development of DCM.Here,
we identiﬁed a total of 1828 differentially methylated probes (DMPs) using the Inﬁnium 450K
HumanMethylation Bead chip by comparing the methylomes between 18 left ventricles and 9 right ventricles.
Alterations in DNA methylation levels were observedmainly in lowly methylated regions corresponding to pro-
moter-proximal regions, which become hypermethylated in severely affected left ventricles. Subsequent mRNA
microarray analysis showed that the effect of DNAmethylation on gene expression regulation is not unidirection-
al but is controlled by the functional sub-network context. DMPs were signiﬁcantly enriched in the transcription
factor binding sites (TFBSs) we tested. Alterations in DNA methylation were speciﬁcally enriched in the cis-
regulatory regions of cardiac development genes, the majority of which are involved in ventricular development
(e.g., TBX5 and HAND1).
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Dilated cardiomyopathy (DCM) is one of the most frequent types of
heart failure and is characterized by a ventricular idiopathic dilation in
mass and volume and a thickened ventricular wall (hypertrophy) [1].
This condition more severely affects the left ventricle (LV) than the
right ventricle (RV). As a result, the DCM-affected weakened and en-
larged heart cannot efﬁciently pump blood out of the ventricle despite
normal blood ﬂow through the failed heart due to a process called re-
modeling [2]. DCM-affected patients suffer from a syndrome that affects
numerous organs [3], including the lungs and liver [4]. A clear cause of
the disease is not known, but several factors may be involved in its ini-
tiation, including inherited genetic mutations, infections, abnormal
neuronal or cytokine activation, and toxic agents [5,6]. Regardless of
the type of initiating cause, the end stage of the disease leading to. This is an open access article underheart failure is suspected to converge on a commonmolecular pathway
[7,8].
Several groups have conducted microarray or RNA-seq experiments
to identify differentially expressed genes (DEGs) between normal
hearts and failing hearts with different etiologies, including DCM [9,
10]. Some of these transcriptome-based expression analyses showed al-
tered expression of genes encoding cytoskeletal proteins (e.g., actin, tro-
ponin,myosin) and ion channels inDCM-affected hearts comparedwith
normal hearts [11,12]. For instance, Barrans et al. [9] identiﬁed 111
DEGs, including sarcomeric and cytoskeletal protein-coding genes,
using the transcriptome derived from 7 DCM-affected hearts and 5 nor-
mal hearts. Yang et al. [10] identiﬁed 12 DEGs, including Beta-Actin
(ACTB) and Myomesin 1 (MYOM1), from microarray experiments with
2 DCM hearts, 1 normal heart and 1 ischemic myopathy (ICM) heart.
Other studies reported lipid catabolism genes or apoptosis-regulating
genes as DEGs between two hearts with different statuses. For instance,
Grezeskowiak et al. [11] identiﬁed 364 DEGs, including genes involved
in lipid metabolism and fatty acid oxidation, using 10 DCM samples,
and Yung [12] reported 165 DEGs, including apoptosis-related genes,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
85B.-S. Jo et al. / Genomics 108 (2016) 84–92in a transcriptome analysis of 6 DCMpatient hearts and 5 normal hearts.
Dysregulation of these genes was often associated with the severity of
heart failure [13]. Additionally, the binding of cardiac transcription fac-
tors to the promoters of the altered genes was linked to the dysregula-
tion of these genes in the affected hearts [14].
Epigenomic changes, such as DNA methylation and histone modiﬁ-
cations, have also been demonstrated to be involved in failing hearts
with diverse etiologies [15]. DNA methylation, which is a process by
whichmethyl groups are attached to the 5th carbon position of cytosine
of CpG dinucleotides (CpGs) by one of several methyltransferases, sta-
bly marks the expression of genes in speciﬁc cell types. Genome-wide
proportions of CpGs are generally very low, and CpGs usually exist in
clusters called CpG islands (CGIs). Approximately 70% of mammalian
promoters are known to be CGI-containing promoters [16]; abnormal
alteration of CpG methylation in these promoters causes the deteriora-
tion of heart developmental programs andmay contribute to congenital
heart disease [17]. Altered DNAmethylation in CGIs can also cause can-
cers [18]. An increased level of DNAmethylation in the promoter region
of genes is generally associated with the repression of gene expression
[19]. However, Wu et al. reported that increased DNA methylation oc-
curring in genomic regions other than the promoters can enhance tran-
scription by antagonizing Polycomb repression [20]. As in the search for
DEGs, differentially methylated probes (DMPs) are generally identiﬁed
by comparingDNAmethylation proﬁles between two opposing samples
[21]. Indeed, distinct DNA methylation changes were observed in the
promoter and gene body regions of the cardiac genome in failing hearts
[22].
Alterations in epigenomic regulation may be related to the altered
gene expression observed in the above-described transcriptome exper-
iments between normal and failing hearts. However, reports regarding
the levels of DNA methylation and the severity of heart failure have
been contradictory [23,24]. Koczor et al. [23] demonstrated that DNA
hypermethylation was predominant in DCM, with N90% of the 158
DEGs altered by differential methylation patterns in the promoter re-
gions. In contrast, Movassagh et al. [24] argued that promoters in end-
stage failing hearts were more hypomethylated.
Here, we performed DNA methylation proﬁling using the Inﬁnium
450KHumanMethylation BeadChip (‘450K’ chip) andmRNAexpression
proﬁling using the Human HT-12 v4 Expression BeadChip (‘HT-12’
chip) to identify the molecular alterations underlying the pathogenesis
of DCM.We identiﬁed not only several genes already known to be asso-
ciatedwithDCMbut also novel geneswhoseDNAmethylation and gene
expression patterns were altered.
2. Materials and methods
2.1. Ethics statement
This study was performed in accordance with the principles of the
Declaration of Helsinki andwas approved by The SamsungMedical Cen-
ter (Seoul, Korea) Institutional Review Board (IRB) (No. 2012-02-065).
Each participant provided written informed consent, and the IRB ap-
proved the consent procedure.
2.2. Preparation of human cardiac tissue samples from DCM patients
DNA samples for DNAmethylation proﬁling using the 450K chip [25]
were obtained from human DCM patients. Surgical specimens from 20
patientswithDCMwere obtained from three differentKoreanhospitals:
AsanMedical Center (AMC), SamsungMedical Center (SMC), and Seoul
National University Hospital (SNU). A total of 18 left ventricle (LV) apex
and 9 right ventricle (RV) wall samples were collected, including two
paired samples derived from the same patients (Table S1 in Ref. [57]).
Of the 27 samples analyzed, the mean ages of the LV and RV samples
were 54.9± 4.0 yr and 57.2± 6.5 yr, respectively, and therewas no sta-
tistical difference in ages between the LV and RV samples (p=0.77, notsigniﬁcant). The sex ratio between LV and RV sampleswas identical, i.e.,
no bias in sex was found between the LV and RV samples. These values
of ‘age’ and ‘sex’ are shown in Table S1 in Ref. [57]. Each sample was
tagged by a label with the hospital name and a number (e.g., AMC01,
SMC01, SNU01, etc.). A subset of tissue samples, including a hypertro-
phic cardiac apex, was snap-frozen in liquid nitrogen (LN2). Samples la-
beledwith LV2were derived from thewalls of the apex in the lower side
of the LV, which was often used for DCM-related studies [26]. Samples
labeled with LV1 were obtained from the proximal site of the LV due
to a lack of apex tissues. RV1 samples were obtained from the right ven-
tricular anterior wall and were extracted using the criteria for normal
hearts, including the normal thickness of the ventricle wall and normal
pumping with a normal blood ﬂow.
Genomic DNA and total RNAwere extracted from the cells using the
QIAamp DNA mini kit and the RNeasy mini kit with RNeasy mini spin
columns (Qiagen Inc. Hilden, Germany).
DNA samples for themRNAmicroarray experiment using the ‘HT-12
chip’ were prepared in the same way as the sample preparation for the
methylation proﬁling described above. A total of 22 LV and8RV samples
were used for the mRNA experiment. Like the samples used for the
methylation study, the ‘age’ and ‘sex’ biases were investigated for
these expression data as well. Of the 30 samples analyzed, the mean
ages of the LV and RV samples were 52.8 ± 4.0 yr and 50.4 ± 8.1 yr, re-
spectively, and there was no statistical difference in ages between the
LV and RV samples (p = 0.79, not signiﬁcant). In addition, there was
no sex bias between the samples. These values are shown in Table S1
in Ref. [57]. Note that the tissue samples used for the ‘450K chip’ analysis
were not all paired with the tissue samples for the ‘HT-12 chip’ primar-
ily because the amount of tissue samples required for performing the
two experiments simultaneously was insufﬁcient.
All our data used in the present work were deposited into Gene Ex-
pression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=erezeeaojpyvbqn&acc=GSE81339) (accession number:
GSE81339).
2.3. Pre-processing of the ‘450K chip’ data
The Inﬁnium HumanMethylation450 BeadChip (Illumina, Inc., San
Diego, CA, USA), which interrogates 482,421 CpG sites, 3091 non-CpG
sites and 65 random single nucleotide polymorphisms (SNPs) and
covers 21,231 RefSeq genes [25], was used for methylome proﬁling in
the present study. Illumina intensity data (IDAT) ﬁles were imported
to obtain detailed bead-level information. To focus on CpG sites, non-
CpG sites and SNPs were removed during the ﬁltering process. Probes
on chromosomes X and Y were removed to eliminate potential artifacts
originating from the presence of a different proportion of males and fe-
males. Additionally, probes with a detection p-value N 0.01 in all sam-
ples and probes for which the beta values (β-values) had low
standard deviations were also excluded. Color bias adjustment and
background correction were implemented to eliminate systematic bias
using lumi [27] (Fig. S1 in Ref. [57]). Then, we performed an adjustment
for probe type bias between the Inﬁnium I and Inﬁnium II assays using
beta-mixture quantile normalization (BMIQ) on the β-values [28] (Fig.
S2 in Ref. [57]).
The β-value was calculated as the intensity of the methylated chan-
nel divided by the sum of the methylated and unmethylated probe in-
tensities. The β-value ranges between 0 (completely unmethylated)
and 1 (completely methylated) and can be broadly interpreted as the
percentage of methylation for a particular CpG.
2.4. Data analysis
Statistical analyses and plotting experiments were performed using
R version 3.2.2 [29]with the Bioconductor 3.1 package. Other batch jobs
were performed with custom-built Python scripts.
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Raw intensity data (Illumina 450K IDAT ﬁles) were parsed into the
Bioconductor RnBeads package [30], which is an R package for the com-
prehensive analysis of DNA methylation data derived from any experi-
mental protocol that provides single-CpG resolution. The RnBeads
program manual explains in detail how DMPs are selected. Brieﬂy, the
priority-ranked list of DMPs was selected by combining three different
criteria as follows: (1) the difference in the mean methylation levels
of the two groups being compared, (2) the ratio of the methylation of
the two groups divided by the mean methylation, and (3) a p-value
computed using the linear model for microarray data (limma) method
[31]. A rank was assigned for each site based on each of these three
criteria (http://rnbeads.mpi-inf.mpg.de/publication/example_3/
differential_methylation.html). From these rank, the maximum (i.e.,
worst) rank was chosen as a combined rank among the three different
ranks, resulting in the provision of a combinedRank cutoff by RnBeads.
Thus, the lower the combined rank, the higher the chance of having
stronger evidence for differential methylation.
Hierarchical linear models from the limma package were employed
andﬁtted using an empirical Bayes approach onderivedM-values (M=
log2β/(1−β)). A total of 13,170 DMPs were identiﬁed by adjusting the
combinedRank cutoff. Then, these DMPs were ﬁltered by the detection
of a N 5% difference in the mean β-value between the LV and RV tissues
with an FDR adjusted p-value (Benjamini-Hochberg) b 5.0e-04 to ﬁnd
highly signiﬁcant DMPs. Overall, we identiﬁed a total of 1828 signiﬁcant
DMPs allocated to 1525 genes.
2.6. Identiﬁcation of DEGs between RV and LV
A microarray experiment was performed with mRNA samples de-
rived from 22 LV and 8 RV cardiac tissue samples using the ‘HT-12
chip’ to identify DEGs. Probes with a detection p-value N 0.01 in any
sample were removed, and a quantile normalization method was ap-
plied to reduce potential sources of non-biological variation among
samples. Then, a two-sample t-test was performed between the LV
and RV cardiac tissues, from which a total of 3347 DEGs with a FDR ad-
justed p b 0.05 were selected.
2.7. Annotation of genic regions for the sites characterized by the 450K chip
Genomic locations of CGIs were obtained using the reference geno-
mic position provided by the UCSC genome browser [32]. The DNase I
hypersensitive sites (DHSs), enhancer regions, and transcription factor
binding sites (TFBSs) archived as part of the encyclopedia of DNA ele-
ments (ENCODE) project [33] were also downloaded from the UCSC
browser. All annotations are based on human genome build 19
(GRCh37).
2.8. Clustering of DEGs in the context of the DNAmethylation of a functional
interaction network
Clustering analysis of differentially methylated genes was per-
formed using Cytoscape (ver. 3.2.0, http://www.cytoscape.org/) with
the Reactome functional interaction (FI) plug-in (ver. 4.2.0) [34]. The
resulting sub-networkswere subsequently tested for pathway overrep-
resentation using ‘Pathway Enrichment’ terms. The direction (up- or
down-regulation) of the change in gene expression in each sub-net-
work was determined by log2-transformed fold changes in the mean
expression of genes belonging to the sub-networks.
2.9. Characterizing DMP-containing genes
We used GREAT (Genomic Regions Enrichment of Annotations
Tool) [35] with the default parameters to ﬁnd functional terms
for the nearest gene arising from the DMPs (http://bejerano.stanford.edu/great/public/html/). The binomial test was used for
gene ontology (GO) enrichment in the GREAT analysis to conﬁrm
its signiﬁcance. We focused on the GO Biological Process, Mouse
Phenotype and Mouse Expression categories. The protein-protein
interaction network for the 45 genes characterized by GREAT was
analyzed with GeneMANIA (ver. 3.4.0) [36] performed with the
Cytoscape plugin of the Cytoscape (ver. 3.2.0) network visualiza-
tion and analysis environment; ‘physical interaction’ was chosen
with the default options, and the ‘2013 consolidated-pathway’
[37] option was selected to ﬁnd associations among the 45 genes.
3. Results
3.1. A summary of the methylome obtained from DCM-affected LV and RV
in humans
DNA samples were obtained from 18 LV apexes and 9 RV walls (see
Materials and methods). LV function in DCM patients is generally more
impaired than RV function, although the RV is compromised as well [1].
RV samples (explants retrieved using the criteria for normal hearts)
were selected as a proxy for normal hearts (i.e., controls) due to the dif-
ﬁculty in tissue sampling from normal human hearts in comparison
with LV samples (i.e., cases).
The ‘450K chip’ is capable of measuring DNAmethylation at approx-
imately 500,000 promoters using probes for 485,577 CpG sites. A total of
463,504 CpG sites were selected in the present study for analysis after
extensive data cleaning (Materials and methods), correction for back-
ground ﬂuorescence, and quantile normalization (Figs. S1 and S2 in
Ref. [57]).
The global distribution of DNAmethylation conﬁrmed previousﬁnd-
ings regarding the DNA methylation patterns occurring in cells or tis-
sues. (1) Most CpG sites in CGI regions were maintained in low
methylation states with a β-value b 0.2 (i.e., CGIs in areas with the
highest CpG density had lower β-values) (red line in Fig. S3A in Ref.
[57]). (2) In contrast, the CpG sites in the open sea and shelf regions ex-
hibited high methylation levels with a β-value N 0.8 (cyan and brown
lines in Fig. S3A in Ref. [57]). (3) CpG sites in the shore regions showed
a bimodal distribution of methylation (purple line in Fig. S3A in Ref.
[57]). (4) The proximal-half of promoter regions tended to have lower
methylation levels compared with the distal-half of promoter regions,
whereas gene body methylation levels were generally higher than pro-
moter methylation levels (Fig. S3B in Ref. [57]). (5) The global methyla-
tion pattern was similar between the LV and RV and exhibited a typical
bimodal pattern (Fig. S4A in Ref. [57]). (6) Similarly, therewas nodiffer-
ence in the locational distribution of DNAmethylation between the two
opposing tissue samples (Fig. S4B in Ref. [57]). Consistently, most geno-
mic patterns of methylation were previously found to be largely main-
tained during cellular processes, with alterations only occurring in
local regions under speciﬁc conditions [38]. However, our study showed
that the slight alterationswere enough to differentiate the LV (case) and
RV (control), as shown by themulti-dimensional scaling (MDS) analysis
performed for the totalmethylome, which consisted of the 463,504 CpG
probes obtained fromed the ‘450K chip’ in different genomic contexts
from which the probes were derived (Fig. S5 in Ref. [57]).
3.2. Identiﬁcation of DMPs related to DCM severity
Subsequently, we identiﬁed DMPs to investigate alterations in the
DNA methylation pattern in the two different heart conditions. In the
present study, a total of 13,170 positions were automatically selected by
the combinedRank threshold of the RnBeads software (see Materials
and methods) of 72,880 as putative DMPs between LV and RV. The
RnBeads software developedbyBock and colleagues [30]was successfully
used to identify DMPs in glioblastoma samples. The combinedRank
threshold alone, estimated by three different criteria, should be strong
enough for detecting DMPs (Materials and methods); however, we
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large methylation differences between case and control. As stated above,
the absolute size difference of methylation alteration between the LV and
RV samples for each CpGwas small but statistically signiﬁcant. Therefore,
the selectedprobeswere reﬁned further basedon the absolute differences
inmethylation by a β-value difference between case and control ≥5% and
an FDR b 5.0e-04 (Fig. S6 in Ref. [57]). Consequently, a total of 1828
probes corresponding to the positions of 1525 genes were identiﬁed
(Fig. S6; Table S2 in Ref. [57]) as DMPs.
3.3. RVs are a valid proxy of normal hearts
We ﬁrst evaluated whether RV samples can be a proxy for normal
hearts by investigating the extent of the similarity of the DNAmethyla-
tion pattern of RVs compared to that of unaffected normal hearts. Fortu-
nately, we found a dataset containing methylome data derived from 2
LVs and 1 RV of normal (unaffected) hearts produced by the NIH
Roadmap Epigenomics Project (http://www.roadmapepigenomics.
org) [39], although the data were generated using a different platform
technique, i.e., whole genome bisulﬁte sequencing. These datasets
were downloaded from the GEO (GEO, http://www.ncbi.nlm.nih.gov/
geo/) database (accession number: GSE16256). We performed a meta-
analysis after combining these methylation data with our affected LV
and RV datasets. As shown in Fig. S7 in Ref. [57], themethylation in nor-
mal hearts clusteredmore closely to our RV samples than to the affected
LVs in the heatmap combinedwith hierarchical clustering analysis (Fig.
S7A in Ref. [57]). The unaffected LVs clustered together with the unaf-
fected RV and our RVs rather than with our affected LVs. These results
indicate that RV samples (Fig. S7B in Ref. [57]), which represent the
less severely affected part of DCM-affected hearts, can be an appropriate
substitute for the normal control against the more severely affected LV
samples.
3.4. Random forest analysis conﬁrms the 1828 DMPs are a good classiﬁer
between case and control hearts
To prove that the 1828 DMPs are a good classiﬁer demarcating two
opposing heart samples, the ‘random forest’ algorithm was applied to
our analysis. A schematic of this analysis is depicted in Fig. S8 in Ref.
[57]. Random forest, a popular machine-learning algorithm developed
by Liaw and Wiener [40], was applied to ﬁnd so-called important vari-
able probes (IVPs) of our DCM methylome analysis. Random forest
here means a collection of decision trees selected by 10,000 random
subset samplings, i.e., training subsets and test DCM subsets, from the
27 DCM 450K methylome samples. A total of 7000 IVPs were identiﬁed
by the ‘random forest’ technique. Subsequently, the 7000 IVPs were
matched to the 1828 DMPs, and we found that the fraction of IVPs in
the 1828 DMPs was approximately 50.7% (Fig. S9 in Ref. [57]).
Subsequently, to test whether the fraction of IVPs in the 1828 DMPs
can be generated by random expectation, a permutation experiment
was performed using the IVP fractions estimated for 1828 randomly
chosen probes during 1000 iterations. None of the randomly chosen
1828 probes produced over 50.7% during 1000 iterations (p b 0.001,
Fig. S9 in Ref. [57]). This result clearly indicates that the 1828 DMPs
we identiﬁed are good and signiﬁcant classiﬁers that can differentiate
the two opposing heart samples.
3.5. Hypermethylation is more prominent in the LV
Heat map analysis combined with hierarchical clustering was per-
formed to investigate whether the 1828 DMPs clearly differentiated be-
tween the LV (case) and RV (control) (Fig. 1A). Approximately 70% of
the DMP-containing genes (1284/1828) in the case samples showed in-
creased levels of DNA methylation (i.e., hypermethylation), whereas
only 30% of the DMP-containing genes (544/1828) showed decreased
levels of DNA methylation (i.e., hypomethylation) (Fig. 1B).We subsequently evaluated whether there was bias in the distribu-
tion of increased and decreased methylation across the genic locations.
We calculated the proportions of hyper- and hypo-methylated probes
among the 1828 DMPs based on genic location (Fig. 2). Interestingly,
more of the CpG sites detected in promoter-proximal regions such as
TSS200 (200 bp upstream of transcription start site (TSS)), the ﬁrst
exon, and the 5′ untranslated region (UTR) were hypermethylated,
whereas more of the CpG sites in the promoter-distant regions were
hypomethylated (Fig. 2A). Consistently, Fig. 2B showed that CpG sites
in CGIs (i.e., representing promoter-proximal CGIs) were more likely
to be hypermethylated, whereas CpG sites in CGI shores and shelves
were more likely to be hypomethylated. The lowest proportion of
hypermethylation was detected in the 3′UTR and CGI shelves (Fig. 2A
and B). The same distribution of methylation alterations across the
genic regions was observed when original DMP selection threshold,
i.e., 72,880 of combinedRank, was applied (Fig. S10 in Ref. [57]). Nota-
bly, CpG sites in the moderately methylated TSS1500 (1500 bp up-
stream of TSS) tended to be hypermethylated.
Taken togetherwith the data in Fig. 1, these results indicate that pro-
moter-proximal regions (i.e., lowly methylated regions) experience
hypermethylation (i.e., increased methylation), whereas promoter-dis-
tant regions (i.e., highly methylated regions) experience hypomethyla-
tion (i.e., decreased methylation) during DCM pathogenesis. As
described in the Introduction Section, Koczor et al. [23] reported the
same pattern of methylation alteration in DCM.
3.6. Effect of DNA methylation on the regulation of gene expression is not
unidirectional
One of the well-established functions of DNA methylation is as a
negative regulator of gene expression [41,42]. To investigate whether
the DMPs identiﬁed in DCM heart samples supported the conventional
hypothesis concerning DNA methylation and gene expression, the
DMP-containing genes were matched to DEGs estimated by mRNAmi-
croarray experiments between case and control. The microarray mRNA
expression experiments were performed for 22 LV (case) and 8 RV
(control) samples (Table S1 in Ref. [57]). A total of 3347 DEGs were
identiﬁed using 11,720 valid RefSeq genes (after noise ﬁltering) using
a t-test (FDR p b 0.05) (Table S3 in Ref. [57]).
Only 253 DMP-DEG pairs were derived from the 1828 DMPs that
were ﬁltered through the more stringent thresholds described above;
therefore, the original threshold of RnBeads for detecting DMPs, i.e.,
72,880 of combinedRank, was applied to increase the number of DMP-
DEG pairs and increase statistical power. Consequently, a total of 984
DMP-DEG pairs were selected in both the DEG and DMP lists (Table
S3; Fig. 1A in Ref. [57]) for the following analyses.
Using these 984 DMP-DEG pairs, we investigated how DNAmethyl-
ation affected gene expression. Unexpectedly, the effect of DNAmethyl-
ation on gene expression was bidirectional instead of unidirectional
(Fig. 1B in Ref. [57]). In otherwords, some geneswith higher DNAmeth-
ylation levels were associated with increased gene expression, contra-
dictory to conventional expectation. Only 469 of the 984 DMP-DEG
pairs showed the expected negative relationship, which consisted of
two patterns: i.e., increasedmethylation associatedwith down-regulat-
ed gene expression (‘Hyper-Down’) and vice versa (‘Hypo-Up’) (red
bars in Fig. 1B in Ref. [57]). The remaining 515 DMP-DEG pairs
contradicted the proposed negative relationship between DNAmethyl-
ation and gene expression (blue bars in Fig. 1B in Ref. [57]), presenting
‘Hyper-Up’ and ‘Hypo-Down’ patterns.
3.7. Regional context-dependent effect of DNA methylation in gene expres-
sion regulation
We hypothesized that this unexpected ﬁndingmay be due to differ-
ences in the regulatory roles of methylation in the gene body and 3′UTR
versus in promoter-upstream regions [43]. To test this hypothesis, we
Fig. 1. Heat map analysis of signiﬁcant DMPs. (A) Heat mapping combined with hierarchical clustering was performed using the 1828 DMP CpG sites. The color-coded scale (blue =
hypomethylation and red = hypermethylation) for the relative methylation M-value is indicated at the top right of the ﬁgure. Hierarchical clustering of rows and columns represents
M-values of the CpG sites and patients' samples, respectively. (B) Pie chart describing the 1828 DMPs exhibiting proportions of increased or decreased DNA methylation in the LV
compared with the RV.
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tween the ‘negative-relation’ and ‘positive-relation’ groups across the
genic regions by examining those genes with the top and bottom 20%
of expression fold-changes among the 984DMP-DEGpairs. This allowed
us to investigate which type of methylation, ‘Hyper’ or ‘Hypo’, had a
greater inﬂuence on the expression changes in each relation group
(negative and positive). Brieﬂy, methylation densities coupled to the
particular expression changes were estimated and plotted; the red
and blue lines in Fig. 3 indicate methylation densities coupled to up-Fig. 2. Distribution of the 1828 DMPs in different genic regions. The 1828 DMPswere divided in
sites). Distributions of the 1828DMPswere investigated throughout each genic region. Proporti
genic locations divided into TSS1500, TSS200, 5’UTR, ﬁrst exon, gene body and 3’UTR, and (B
proportions of hyper- and hypomethylated sites were compared to the proportion of all met
p b 0.05 by the chi-squared test for comparisons.regulated and down-regulated DEGs, respectively, from which the
methylation densities of the 984 DMP-DEG pairs were investigated for
the four different pair types: ‘Hypo-Down’ and ‘Hypo-Up’ pairs (left
panels of Fig. 3) and ‘Hyper-Down’ and ‘Hyper-Up’ pairs (right panels
of Fig. 3).
We found that the methylation alterations that occurred in promot-
er-upstream regions tended to be negatively linked to the gene expres-
sion changes as expected by conventional wisdom; the densities of
‘Hypo-Up’ and ‘Hyper-Down’ pairs were higher than those of ‘Hypo-to two groups: hypermethylated DMPs (‘Hyper’ sites) and hypomethylated DMPs (‘Hypo’
ons of ‘All sites (all methylated sites)’, ‘Hyper’ sites, and ‘Hypo’ siteswere calculated by (A)
) genomic locations divided into CGI, CGI shore, and shelf by CGI-context. Subsequently,
hylated sites detected by the 450K chip. An asterisk denotes a statistical signiﬁcance at a
Fig. 3.Methylation density of Up-/Down-DEGs in different genic regions. Gene pairs with
the top 20% of up-regulated expression fold-changes and bottom 20% of down-regulated
expression fold-changes were selected among the 984 DMP-DEG pairs. The x-axis
represent the fold-changes in methylation levels between RV and LV; negative values
and positive values represent ‘Hypo’ and ‘Hyper’, respectively. The densities of ‘Hypo’
and ‘Hyper’ are plotted on the left (i.e., less-than-zero side) and right side (greater-than-
zero side), respectively. The red lines represent the methylation densities of genes with
the top 20% of up-regulated expression fold-changes (‘Up’), whereas the blue lines
represent the methylation density of genes with the bottom 20% of down-regulated
expression fold-changes (‘Down’).
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genes such as TSS1500, TSS200, and 5’UTR. In contrast, the methylation
alterations in the gene body and distal regions to the promoter, such as
ﬁrst exon, gene body, and 3′UTR, were positively associated with the
gene expression changes: the densities of ‘Hypo-Up’ and ‘Hyper-
Down’ pairs were lower than the densities of ‘Hypo-Down’ and
‘Hyper-Up’ pairs, respectively (Fig. 3).
The same analysis was also applied to the CpG sites located in the
DHSs and enhancer regions (Fig. 2 in Ref. [57]). Ninety-seven of the
469 DMPs (20.7%) and 49 of the 515 DMPs (9.5%) in the DHSs
corresponded to the ‘negative-’ and ‘positive-relation’ group, respec-
tively. Overall, the densities of ‘Hypo-Up’ and ‘Hyper-Down’ pairs (i.e.,
the ‘negative-relation’ group’) were higher than those of the ‘Hypo-
Down’ and ‘Hyper-Up’ pairs (i.e., the ‘positive-relation’ group) in the
DHSs and enhancer regions (Fig. 2 in Ref. [57]), although the density
of ‘Hyper’- methylation in enhancer regionswas not clear. Interestingly,
we found that the same ‘negative-relation’ pattern was predominant in
promoter-upstream, DHS, and enhancer regions; however, there were
more methylations of ‘Hypo’ status in DHSs and enhancer regions and
more methylations of ‘Hyper’ status in promoter and promoter-up-
stream regions.
This analysis of methylation densities in different genic regions
clearly shows thatmethylation in different genic regions plays different
regulatory roles in gene expression. A full understanding of the regula-
tion of gene expression by DNAmethylation requires an understanding
of the complex roles of methylation levels in different genic regions.
3.8. Gene expression is regulated by a systemic combination of changes of
DNA methylation in functional networks
We next investigated how systemic DNA methylation patterns that
occur in groups of genes in a highly connected, functional module affect
the expression of genes within the sub-network. The DMPs obtained
from the TSS1500 and TSS200 regionswere selected for this analysis be-
cause promoters and their nearby regions are primarily responsible for
gene expression regulation.A functional interaction network was constructed using the 984
DMP-DEG pairs using the Reactome FI Cytoscape Plug-in (see
Materials and methods) (Fig. 3 in Ref. [57]). Brieﬂy, the interactions
from Reactome and those derived from the pathway databases were
combined into the Reactome FI dataset (http://cancer.cellmap.org/)
[33]. Next, pair-wise interactions were generated, and spectral
partitioned clustering was obtained to identify internal modular sub-
structures [44]. The eight top-ranked functional sub-networks indicated
by colored modules to contain the largest number of genes were ex-
tracted using the Reactome FI dataset (Fig. 3 in Ref. [57]). The color
(ranging between blue and pink) of each module was determined by
the average expression fold changes of the genes within each sub-net-
work. The patterns of methylation indicated by TSS200 or TSS1500
that were responsible for altering gene expression in a sub-network
were determined by the number of DMP genes found within that sub-
network. For instance, the genes in the sub-network enriched in the
‘Regulation of actin cytoskeleton’pathway tended tobedown-regulated
and were determined to bemainly controlled by themethylation of the
TSS1500 region (Fig. 3 in Ref. [57]). Interestingly, hypermethylated and
hypomethylated DMP genes in TSS1500 clustered together in this par-
ticular sub-network. Because the expression in that sub-network mod-
ule was down-regulated on average, the hypermethylation rather than
hypomethylation of TSS1500 might play a key role in the decreased ex-
pression of the genes in this sub-network.
Notably, genes in sub-networks such as ‘Regulation of actin cytoskel-
eton’ and ‘Nfat and hypertrophy of the heart’ (i.e., genes known to be in-
volved in DCM pathogenesis) were down-regulated; this down-
regulation might be controlled by hypermethylation in TSS1500 and
TSS200, respectively. This result is consistent with the result depicted
in Fig. 3 showing that hypermethylated DMP genes are more enriched
in the TSS1500 and TSS200 regions.3.9. Analysis of differentially methylated TFBSs in the LV and RV
Next, we investigated whether the differential methylation patterns
detected in thepresent studywere located at functional regulatory sites.
To explore this question, we ﬁrst determined the proportions of the
1828DMPs thatwere actually located at the transcription factor binding
sites (TFBSs) of genes. Chromosomal locations for a total of 148 TFBSs
were downloaded from the ENCODE database through the UCSC ge-
nome browser. These TFBSs were matched to the chromosomal posi-
tions of the 1828 DMPs. The top 10 TFBSs occupied 31% of the total
TFBSs of the 1828 identiﬁed DMPs (Fig. 4).
Overall, the fractions of all of the TFBSs in the DMPs we tested were
signiﬁcantly increased when the fractions of TFBSs in the DMP positions
were compared with the total genome (p b 0.01) (upper panel of Fig.
4), indicating that the alterations of DNA methylation levels in the TFBSs
were signiﬁcantly enriched in cases compared to controls. We performed
this experiment for hypermethylated DMPs and hypomethylated DMPs
separately and found that the most enrichment occurred in
hypermethylated DMPs (Fig. 4). Interestingly, CCCTC-binding factor
(CTCF) was the only exception andwas present in a signiﬁcantly reduced
proportion of the DMPs. This result indicates that methylation at CTCF
binding sites tends to be stably maintained during DCM pathogenesis.
The stability of methylation in the CTCF binding sites in different physio-
logical states was previously reported as well by Medvedeva et al. [45].
Consistent results were obtained when the 984 DMPs were
matched to DEGs in pairs. Using the 984 DMP-DEG pairs, we investi-
gated whether the methylation alteration that occurred in the CTCF
binding sites had the weakest effect on expression change. The
Wilcoxon signed-rank test was performed to test for a difference be-
tween expression change and methylation alteration for a gene in
which a speciﬁc TFBS is located. The methylation alteration that oc-
curred in the CTCF binding sites was associated with the smallest ex-
pression changes (lower panel of Fig. 4).
Fig. 4. Signiﬁcant enrichment of TFBSs in the DMPs. The genomic locations of 148 TFBSs
were downloaded from the UCSC genome browser. The downloaded TFBSs were
matched to the 1828 DMPs. The proportion of each TFBS in the 1828 DMPs was
estimated and compared with the proportion of each TFBS in the total genomic sites.
The black and gray boxes divided on the left side of each section represent TFBS
proportions estimated from the hypermethylated and hypomethylated DMPs,
respectively. Each white bar on the right side of each section represents the proportion
of the given TFBS per all TFBSs located across the genome. Statistical signiﬁcance was
assessed at p b 0.01 using a chi-squared test (upper panel). The relationship between
methylation alteration in each TFBS and expression changes of genes carrying the
altered methylation of a speciﬁc TFBS was investigated by two-sided Wilcoxon signed-
rank tests. p-Values converted to negative logarithm base 10 are indicated along the y-
axis (lower panel).
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Subsequently, we investigatedwhether the 1828DMPswere located
in known functional cis-acting regulatory sites. We found that 45 genes
of the 1828 DMPs were revealed to be in functional non-coding cis-act-
ing regions by conducting a GREAT analysis, developed byMcLean et al.
[35] (http://bejerano.stanford.edu/great/public/html/) (Table 1 in Ref.
[57]) (see Materials and methods).
Interestingly, the GREAT analysis also revealed that the signiﬁcant
categorical terms of the 45 genes included “cardiac left ventricle mor-
phogenesis” (Fig. S11A in Ref. [57]) and “ventricular cardiac muscle tis-
sue development”, which exactly reﬂected themolecular features of the
disease that we expected to ﬁnd in the present work. Mouse knock-out
phenotypeswere searched against these 45 genes; similarly, terms such
as “abnormal interventricular septum muscular part morphology” and
“muscular ventricular septal defect” were located at the top of the list
(Fig. S11B in Ref. [57]). Furthermore, expression analysis using Mouse
Genome Informatics (MGI) showed that these 45 genes were expressed
in “heart tube cardiac muscle” (Fig. S11C in Ref. [57]).
The relationship betweenmethylation alteration and the expression
changes of the 45 genes was conﬁrmed in our DMP-DEG pairs. For in-
stance, decreased methylation in the noncoding cis-regulatory regions
of ‘Heart and neural crest derivatives expressed 1’ (HAND1) and ‘T-
box 5’ (TBX5) were linked to increased mRNA expression levels of
these genes, while increased methylation in the noncoding cis-regula-
tory regions of ‘Fibroblast growth factor 8 (FGF8) and ‘DnaJ homolog
subfamily C member 10’ (DNAJC10) were linked to decreases in their
mRNA expression levels (Fig. S13 in Ref. [57]). HAND1 [46] and TBX5
[47] were previously recognized in the ﬁeld of heart development,
and their genetic alteration can cause severe developmental defects in
the heart. FGF8 is a developmentally important TF, and DNAJC10 is a
chaperone.3.11. Validation through comparison with Koczor et al.'s study
We found a study conducted by Koczor et al. (2013) that identiﬁed
methylation-expression pairs (Accession Number GSE43435) in
human DCM and compared their ﬁndings with our results, even though
Koczor et al.'s study was based on the methylated DNA immunoprecip-
itation (MeDIP) technique rather than the ‘450K chip’ platformwe used
in the present study [23]. Interestingly, Koczor at al.'s ﬁnding was gen-
erally consistent with our result that human DCM patients tended to
present hypermethylation near the TSS (Fig. 1B). The comparison of
our 1828 DMPs to Koczor et al.'s data revealed that 519 DMP genes
and 44 DEGs presented the same directionally positive or negative rela-
tionship in both studies (Fig. 5A). Expectedly, the overlapping genes
were found to bemainly expressed in the heart and cardiacmyocyte tis-
sues, as determined by DAVID tool [48] (Fig. 5B). Themethylation alter-
ations that occurred in the whole CpGs sites of the TBX5 promoter, i.e.,
hypomethylated CpGs in the case group, were further analyzed using
‘Methylation plotter’ [49] (Fig. 5C), and this resultwas assumed to be as-
sociated with the increased expression of TBX5 in the case group (LV)
(Fig. S13 in Ref. [57]). Interestingly, TBX5 was also one of the genes
with increased expression in the case group included in Koczor et al.'s
study (Fig. 5D). Several previous studies have reported that TBX5 plays
an important role in heart development, and heterozygous mutant
mice are born with morphological problems, such as enlarged hearts
and atrial and ventral septum defects [50,51]. We think that Koczor et
al.'s and our ﬁndings on the epigenetic alteration of TBX5 in human
DCMmake sense in this regard.
4. Discussion
DNA methylation is an epigenomic regulatory modiﬁcation that is
important for normal cellular differentiation and development; alter-
ations in DNA methylation can impair normal gene expression and
cause severe disease.Many large-scale DNAmethylationdetection tech-
niques, including microarray-based techniques such as the Inﬁnium
450K HumanMethylation Bead chip, sequencing-based techniques
such as bisulﬁte sequencing, and the combination of antibody-pull
down and next-generation sequencing techniques such as MeDIP,
have been developed and applied to study speciﬁc cases to search for
DMPs [52–54]. However, identifying DEGs based on microarray tech-
niques has long been a research trend in the search for disease diagnos-
tic or prognosis markers, and in recent years, these two research
subjects (DMPs and DEGs) have often been combined to elucidate mo-
lecular alterations in diseases.
Several studies previously demonstrated that alterations in gene ex-
pressionwere associatedwith the pathogenesis of human DCM [55,56];
however, few studies have attempted to identify the alterations in DNA
methylation underlying this pathogenesis. The reason for the lack of
studies of the effects of DNAmethylation onDCM is primarily due to dif-
ﬁculties in tissue sampling (particularly sampling normal hearts);
therefore, we chose to use the RV as a proxy for the normal heart in
the present work.
We demonstrated that alterations in the levels of DNA methylation
between the LV and RV could explain some aspects of heart failure af-
fected by DCM. For instance, the genes involved in ventricular cardiac
muscle development were found to be differentially methylated be-
tween the two samples (i.e., TBX5, HAND1 and NKX2-5). Additionally,
the majority of the genes that were found to harbor cis-regulatory re-
gions with differentially methylated sites were assembled together in
a protein-protein interaction (Fig. S12 in Ref. [57]). Furthermore, several
genes already known to be involved in the DCMpathwaywere found to
be nested in the protein interaction network (Fig. S12 in Ref. [57]).
Another interesting ﬁnding from the present study was that alter-
ations of DNAmethylation in CTCF binding sites were stablymaintained
between the RV and LV, whereas alterations in DNA methylation were
signiﬁcantly enriched in the other top 10 TFBSs. This result may indicate
Fig. 5. Comparison between our DMPs and Koczor et al.'s data. Our methylation and expression data were compared with those from Koczor et al.'s study. (A) Among our 1828 DMPs, a
total of 1130 DMPs located in promoter-proximal regions were selected tomatch Koczor et al.'s data, and 519DMP genes and 44 DEGswere shown to have the same directionally positive
or negative relationship in both studies. (B) An enrichment test using these matched genes as input for DAVID tool generated tissue proﬁles in which these matched genes are
preferentially expressed. The ‘corrected p value’ means the p-value estimated by the Bonferroni correction. The tissue proﬁles with p b 0.05 are indicated in bold. (C) ‘The Methylation
plotter’ web-based tool was used to analyze the methylation alterations that occurred in the whole CpGs of the promoter-proximal regions of TBX5 (i.e., 1500 bp upstream to 500 bp
downstream from the TSS of TBX5). The Kruskal-Wallis test was used to assess the statistical signiﬁcance of this analysis. (D) Box plots of Z-scores, i.e., normalized expression
differences in TBX5, between the control group (RV in our study and Normal in Koczor et al.'s study) and the case group (LV in our study and DCM in Koczor et al.'s study) are shown.
The statistical signiﬁcance was estimated by Student's t-test (p b 0.01).
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ly by DNAmethylation depending on environmental changes. However,
it is unclear why DMPs in the binding sites of the well-established re-
pressive TF CTCF are signiﬁcantly static compared to the whole genome
average, although the stability of methylation in CTCF binding sites has
been previously reported [45].
Taken altogether, DNAmethylation patterns are signiﬁcantly altered
between the LV and RV, and the alterations in turn affect mRNA expres-
sion patterns between two opposing statuses. Certainly, the study of
global DNA methylation changes that occur under different physiologi-
cal conditions can reveal the epigenomic dynamics that control gene ex-
pression during disease pathogenesis.
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